Sign up
Pharma Capital

Preveceutical Medical updates investors on its soluble gel drug delivery R&D

The group is developing a custom soluble gel applicator, it noted
The firm is working on nose-to-brain delivery solutions

Health sciences firm PreveCeutical Medical Inc (CSE:PREV) said preliminary findings on its custom soluble gel applicator are encouraging as it updated on its R&D (research and development) work.

The programme involves testing an array of cannabis strains to commercialise cannabinoid-based soluble gels.

READ: PreveCeutical Medical closes oversubscribed placing and brings in C$6.54mln

Conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver therapeutics far enough into the nasal cavity and are rapidly removed by the body's cleaning mechanisms.

Preveceutical's soluble gel formulations aim to resolve this by providing a fast nose-to-brain delivery of a host of therapeutic agents, including cannabinoids.

The group is developing a custom soluble gel applicator and its research partner, The University of Queensland, has received several prototype soluble gel spray devices from the group's manufacturer.

Although evaluations are ongoing, the preliminary results are promising, said the company.

Preveceutical shares are unchanged at C$0.065.

Why Invest In PreveCeutical Medical Inc? Read More Here

Register here to be notified of future PREV Company articles
View full PREV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.